ABSTRACT Background Baicalin has shown efficacy in various dermatitis models in animals. However, its therapeutic effects on naturally occurring canine atopic dermatitis (cAD) have not been evaluated. Objective To evaluate the efficacy and safety of baicalin in dogs with cAD. Animals 56 client‐owned dogs were enrolled. Materials and Methods All dogs were randomly divided to receive oral baicalin or placebo over a 90day period. All subjects had veterinary evaluations using the Canine Atopic Dermatitis Extent and Severity Index, 4th iteration (CADESI‐04) during the trial and owners were requested to evaluate itching using the pruritus Visual Analog Scale (PVAS) and to complete a quality‐of‐life (QoL) questionnaire at Day (D)0 and D90. Additionally, the transepidermal water loss (TEWL), total serum IgE levels (IgE), complete blood count and serum biochemical results were measured at D0 and D90. Results The significant decreases in CADESI‐04 ( p < 0.001), PVAS ( p < 0.001), TEWL ( p = 0.014), IgE ( p < 0.001) and QoL scores ( p < 0.001) were observed in the baicalin group D90 compared to baseline. When compared to placebo, the baicalin group had significantly lower scores in CADESI‐4 and PVAS ( p < 0.001). A significantly higher proportion of subjects in the baicalin group showed a good‐to‐excellent treatment response (82.1%) compared to those in the placebo group (35.7%). The treatment was well tolerated. Conclusions and Relevance Baicalin had a significant benefit in alleviating pruritus and reducing clinical signs in dogs with mild‐to‐moderate cAD and was well tolerated.
Qian et al. (Wed,) studied this question.